搜索到16986篇“ ADJUVANT“的相关文章
Tongluo Jiedu as an adjuvant therapy for oral cancer
2025年
Oral cancer is one of the malignant neoplasms that present major global health challenge.It is the sixth most prevalent type of cancer in the world,with a high incidence and mortality rate.This letter is a review of the study by Yin et al which was published in the World Journal of Clinical Cases(2024).The study evaluated the effect of Tongluo Jiedu as an adjuvant treatment for oral cancer.Over the years,there has been a continuous search for effective and less invasive treatments for oral cancer.This article emphasizes and discusses various therapeutic options currently available,and it highlights that early intervention and multidisciplinary management are crucial for improving outcomes.Traditional Chinese medicine,particularly Tongluo Jiedu,presents potential complementary approach to co-nventional oral cancer therapies.Future research on Tongluo Jiedu should be focused on validation of its efficacy and safety through large,well-designed clinical trials,as well as better understanding of the molecular mechanisms in-volved,and optimization of therapeutic combinations.Additionally,continuous education of health professionals is key to the effective and safe integration of this traditional medicine into clinical practice.Continuous research is essential for optimization of therapeutic strategies and for addressing the challenges presented by this neoplasm.
Sarah Monserrat LomelíMartínezMelissa Martínez NietoAna Esther Mercado González
关键词:DENTISTRY
新型BC佐剂系统的研究进展
2024年
国外已有应用新型佐剂的疫苗上市,国内除铝佐剂广泛应用于疫苗研发生产外,鲜有其他新型佐剂成功上市。本文针对已应用于疫苗临床研究阶段具有自主知识产权的新型BC佐剂系统的来源、发展历史以及生物学活性和免疫机制的研究进展、安全性评价等作一简要综述,为新型疫苗研发中选择该佐剂提供理论支持。
江秋虹陶立峰(综述)王国治赵爱华
关键词:新型佐剂BCG-CPG-DNA新型疫苗
Adjuvant Rectal Diclofenac for Post Operative Analgesia after Caesarean Section—A Randomized Controlled Study
2024年
BACKGROUND: Pain management following caesarean section still remains a challenge in our environment. Most potent analgesics are either not readily available or expensive. Diclofenac suppository is an NSAID that can be used for postoperative analgesia. It is available and affordable. OBJECTIVE: To compare the efficacy and safety of combined rectal diclofenac and intramuscular pentazocine with intramuscular pentazocine alone for post operative pain control following lower segment caesarean section. METHODOLOGY: A total of 120 women who met the selection criteria scheduled for caesarean section under spinal anaesthesia with bupivacaine were randomized into two equal groups to receive either 75 mg diclofenac suppository 12 hourly for 24 hours or one anusol suppository (the placebo) 12 hourly for 24 hours. Both groups received pentazocine as primary analgesia. RESULT: The primary outcome measure is the proportion of patients with severe pain at 24 hours using the visual analogue rating scale. Secondary outcome measures are the time from surgery to ambulation, Passage of flatus, maternal satisfaction and presence of complications. Statistical analysis was done using spss version 22 and graph pad statistical package. Student T-test was used for continuous variables whereas chi square was used for categorical variables P CONCLUSION: Adjuvant rectal diclofenac is superior to pentazocine alone in the management of pain after caesarean section. Less number of patients had moderate to severe pain at 24 hours post operation. Maternal satisfaction in relation to pain management is better with diclofenac suppository. The levels of complications were comparable in both groups.
Eziaha Eric S. EdeAyodele A. OlaleyeJohn C. IrechukwuUchenna Nelson NwaeduBorniface N. EjikemeVincent Chidiebere AliBartholomew I. Olinya
关键词:PAINDICLOFENACPLACEBOSUPPOSITORY
Survival benefit of adjuvant treatment for ampullary cancer with lymph nodal involvement:A systematic review and meta-analysis被引量:1
2024年
Background:The efficacy of adjuvant treatment(AT)in ampullary cancer(AmC)remains controversial.This systematic review and meta-analysis aimed to evaluate the role of AT for AmC.Data sources:A comprehensive systematic search was performed in PubMed,EMBASE,Cochrane Library,and Web of Science databases.Studies comparing overall survival(OS)and recurrence-free survival(RFS)of patients who underwent AT or not following AmC resection were included.Results:A total of 3971 patients in 21 studies were analyzed.Overall pooled data showed no significant difference in effect on the OS by AT[hazard ratio(HR)=0.998,95%confidence interval(CI):0.768–1.297].No significant difference in recurrence between the AT and non-AT(nAT)groups was noted(HR=1.158,95%CI:0.764–1.755).In subgroup analysis,patients who received AT showed favorable outcomes in the OS compared with those who received nAT in nodal-positive AmC(HR=0.627,95%CI:0.451–0.870).Neither AT consisted of adjuvant chemotherapy with radiotherapy(HR=0.804,95%CI:0.563–1.149)nor AT with adjuvant chemotherapy(HR=0.883,95%CI:0.642–1.214)showed any significant effect on the OS.Conclusions:The effect of AT in AmC on survival and recurrence did not show a significant benefit.Furthermore,effectiveness according to AT strategies did not show enhancement in survival.AT had an advantage in survival compared with nAT strategy in nodal-positive AmC.In cases of AmC with positive lymph nodal involvement,AT may be warranted regardless of detailed strategies.
Min Kyu KimJin Ho ChoiIn Rae ChoSang Hyub LeeJi Kon RyuYong-Tae KimWoo Hyun Paik
关键词:META-ANALYSIS
Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy:a novel delivery system candidate for tumor vaccines被引量:2
2024年
The study of tumor nanovaccines(NVs)has gained interest because they specifically recognize and eliminate tumor cells.However,the poor recognition and internalization by dendritic cells(DCs)and insufficient immunogenicity restricted the vaccine efficacy.Herein,we extracted two molecular-weight Astragalus polysaccharides(APS,12.19 k D;APSHMw,135.67 k D)from Radix Astragali and made them self-assemble with OVA257–264directly forming OVA/APS integrated nanocomplexes through the microfluidic method.The nanocomplexes were wrapped with a sheddable calcium phosphate layer to improve stability.APS in the formed nanocomplexes served as drug carriers and immune adjuvants for potent tumor immunotherapy.The optimal APS-NVs were approximately 160 nm with uniform size distribution and could remain stable in physiological saline solution.The FITC-OVA in APS-NVs could be effectively taken up by DCs,and APS-NVs could stimulate the maturation of DCs,improving the antigen cross-presentation efficiency in vitro.The possible mechanism was that APS can induce DC activation via multiple receptors such as dectin-1 and Toll-like receptors 2 and 4.Enhanced accumulation of APS-NVs both in draining and distal lymph nodes were observed following s.c.injection.Smaller APS-NVs could easily access the lymph nodes.Furthermore,APS-NVs could markedly promote antigen delivery efficiency to DCs and activate cytotoxic T cells.In addition,APS-NVs achieve a better antitumor effect in established B16-OVA melanoma tumors compared with the OVA+Alum treatment group.The antitumor mechanism correlated with the increase in cytotoxic T cells in the tumor region.Subsequently,the poor tumor inhibitory effect of APS-NVs on the nude mouse model of melanoma also confirmed the participation of antitumor adaptive immune response induced by NVs.Therefore,this study developed a promising APS-based tumor NV that is an efficient tumor immunotherapy without systemic side effects.
Nan LiYun ZhangMiaomiao HanTian LiuJinjia WuYingxia XiongYikai FanFan YeBing JinYinghua ZhangGuibo SunXiaobo SunZhengqi Dong
关键词:OVAIMMUNOTHERAPY
Cocktail nano-adjuvant enhanced cancer immunotherapy based on NIR-Ⅱ-triggered in-situ tumor vaccination
2024年
Second near-infrared(NIR-Ⅱ)light triggered in-situ tumor vaccination(ISTV)represents one of the most promising strategies in boosting the whole-body antitumor immunity.While most of previously developed nano-adjuvants for NIR-Ⅱ-triggered ISTV are“all-in-one”formulations,which may indiscriminately damage both the tumor cells and the immune cells,limiting the overall effect of immune response.To overcome this obstacle,we designed a“cocktail”nano-adjuvant by physically mixing hyaluronidases(HAase)-decorated gold nanostars(HA)for NIR-Ⅱlight triggered in situ production of tumor-associated antigens and CpG functionalized gold nanospheres(CA)for immune cells activation.Compared to“all-in-one”formulation,the“cocktail”nano-adjuvants displayed a significantly stronger immune response on NIR-Ⅱlight induced dendritic cells(DCs)mutation and T cells differentiation,greater effect on tumor-growth inhibition,and higher efficacy in inhibition of pulmonary metastases.What is more,increasing the molar ratio of HA to CA led to an enhanced anticancer immune responses.This study highlight the nano-adjuvant formulation effects on the treatment of tumors with multiple targets.
Lilin FanYanwen FengJiang BianAnhong ChenDonglin XieZheng CaoJun Yue
Immunogenicity Evaluation of a SARS-CoV-2 BA.2 Subunit Vaccine Formulated with CpG 1826 plus alum Dual Adjuvant
2024年
Objective The present study aimed to evaluate the immunogenicity of BA.2 variant receptor binding domain(RBD)recombinant protein formulated with CpG 1826 plus alum dual adjuvant.Methods The BA.2 variant RBD(residues 308-548)fusing TT-P2 epitope was obtained from prokaryotic expression system,purification technology and dialysis renaturation,which was designated as Sot protein.The soluble Sot protein formulated with CpG 1826 plus alum dual adjuvant was designated as Sot/CA subunit vaccine and then the BALB/c mice were intramuscularly administrated with two doses of the Sot/CA subunit vaccine at 14-day interval(day 0 and 14).On day 28,the number of effector T lymphocytes secreting IFN-γand IL-4 in mice spleen were determined by enzyme-linked immunospot(ELISpot)assay.The serum IgG,IgG1 and IgG2a antibodies were examined by enzyme-linked immunosorbent assay(ELISA).In addition,the level of neutralizing antibodies(NAbs)induced by Sot/CA subunit vaccine was also evaluated by the microneutralization assay.Results The high-purity soluble Sot protein with antigenicity was successfully obtained by the prokaryotic expression,protein purification and dialysis renaturation.The Sot/CA subunit vaccine induced a high level of IgG antibodies and NAbs,which were of cross-neutralizing activity against SARS-CoV-2 BA.2 and XBB.1.5 variants.Meanwhile,Sot/CA subunit vaccine also induced a high level of effector T lymphocytes secreting IFN-γ(635.00±17.62)and IL-4(279.20±13.10),respectively.Combined with a decreased IgG1/IgG2a ratio in the serum,which indicating Sot/CA subunit vaccine induced a Th1-type predominant immune response.Conclusion The Sot protein formulated with CpG 1826 plus alum dual adjuvant showed that the excellent cellular and humoral immunogenicity,which provided a scientific basis for the development of BA.2 variant subunit vaccines and references for the adjuvant application of subunit vaccines.
Yuhan YanQiudong SuYao YiLiping ShenShengli Bi
关键词:RBDADJUVANTIMMUNOGENICITY
高复发进展风险MIBC根治术后辅助化疗和辅助免疫治疗联合化疗的疗效
2024年
目的探讨高复发进展风险(pT_(2)期伴淋巴结阳性,pT_(3~4a)期伴或不伴淋巴结阳性)肌层浸润性膀胱癌(MIBC)根治术后,辅助化疗和辅助免疫治疗联合化疗的疗效。方法回顾性分析2016年8月至2022年1月天津医科大学第二医院收治的217例高复发进展风险MIBC患者的临床资料。男183例(84.3%),女34例(15.7%);年龄(67.3±8.6)岁。217例均行根治性膀胱切除术+盆腔淋巴结清扫,根据术后接受辅助治疗情况分为观察组147例(67.7%)和治疗组70例(32.3%)。观察组和治疗组的年龄分别为(67.4±9.0)岁和(66.3±7.6)岁(P=0.14);术后病理分期T_(2)期伴淋巴结阳性分别为8例(5.4%)和6例(8.6%),T_(3~4a)期伴淋巴结阳性分别为34例(23.1%)和18例(25.7%),T_(3~4a)期不伴淋巴结阳性分别为105例(71.5%)和46例(65.7%)(P>0.05);肿瘤直径≥3cm分别为118例(80.3%)和54例(77.1%)(P>0.05),<3cm分别为29例(19.7%)和16例(22.9%)(P>0.05)。治疗组70例中,36例(16.6%)术后应用吉西他滨(1000mg/m^(2),第1、8天)和顺铂(75mg/m^(2),第2~4天)方案化疗(化疗组);34例(15.7%)应用免疫检查点抑制剂(静脉滴注信迪利单抗200mg或替雷利珠单抗200mg或特瑞普利单抗240mg,第1天)和白蛋白紫杉醇(200mg,第2天)方案治疗(免疫联合化疗组)。化疗组和免疫联合化疗组的年龄分别为(66.8±8.4)岁和(65.8±6.8)岁(P>0.05);术后病理分期T_(2)期伴淋巴结阳性分别为3例(8.3%)和3例(8.8%),T_(3~4a)期伴淋巴结阳性分别为6例(16.7%)和12例(35.3%),T_(3~4a)期不伴淋巴结阳性分别为27例(75.0%)和19例(55.9%)(P>0.05);肿瘤直径≥3cm分别为30例(83.3%)和10例(29.4%)(P>0.05),<3cm分别为6例(16.7%)和24例(70.6%)(P>0.05)。采用Kaplan-Meier法和多因素Cox回归分析观察组与治疗组术后1、3年的总生存期(OS),以及化疗组与免疫联合化疗组术后1、3年的无病生存期(DFS)。采用美国卫生及公共服务部发布的常见不良事件评价标准分析化疗组和免疫联合化疗组的并发症。结果
李智李智王泽今沈冲张英郎张羽张羽张哲徐勇徐勇
关键词:肌层浸润性膀胱癌辅助化疗毒性作用
基于碳水化合物的佐剂作用机制研究进展
2024年
佐剂是指添加到疫苗中以刺激和增强免疫应答强度或改变免疫应答类型的物质。目前疫苗佐剂种类较多,包括铝佐剂、油乳佐剂和脂质体佐剂等,但临床使用的佐剂很少同时具备高效和低毒两大特点,因此迫切需要一种有效且安全的佐剂。基于碳水化合物的佐剂具有良好的生物相容性和易代谢的优点,同时,基于碳水化合物的佐剂种类广泛,且每种都有不同免疫特性,如基于多糖的佐剂可以增强巨噬细胞的吞噬活性及抗原提呈能力等。并且基于碳水化合物的佐剂还可与Toll样受体、C型凝集素受体等多种受体结合发挥上述免疫活性,但其作用机制尚不完全清楚。故本文基于碳水化合物的佐剂作用机制相关研究进展进行总结梳理,以期为相关佐剂的进一步研究提供参考。
周梦婷宋银娟许健李斌冉多良储岳峰
肝癌术后辅助治疗的研究现状
2024年
肝细胞癌(hepatocellular carcinoma,HCC),简称肝癌,是我国发病率及致死率分别位于第5位和第2位的恶性肿瘤,肝癌的术后复发严重影响患者的预后,而肝癌术后进行辅助治疗是预防肝癌复发的重要手段。尽管国内外有研究证实了部分辅助治疗方案可延缓患者术后复发、延长患者生存期、改善患者预后等,国内也有专家共识对多种辅助治疗方案进行了推荐,包括抗病毒治疗、靶向治疗、免疫治疗、经肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)、肝动脉灌注化疗(hepatic arterial infusion chemotherapy,HAIC)、中医药治疗等,但肝癌术后的辅助治疗在肝癌综合治疗中的应用价值尚未完全明确,辅助治疗的受益人群也无法精准定位,因此肝癌术后辅助治疗的必要性仍存在争议。本文将对国内外进行的肝癌术后辅助治疗研究进行综述。
宁金月黄沾任陈春雷
关键词:肝细胞癌肝癌术后复发

相关作者

叶南慧
作品数:33被引量:195H指数:8
供职机构:福州大学
研究主题:抗氧化 体外实验 抗氧化肽 采光系统 畜禽养殖废水
郑焕钦
作品数:80被引量:317H指数:12
供职机构:教育部
研究主题:弓形虫 克隆 DNA免疫 SAG1 日本血吸虫
陈观今
作品数:87被引量:364H指数:13
供职机构:海南医学院
研究主题:弓形虫 DNA免疫 聚合酶链反应 SAG1 体外扩增
郭虹
作品数:35被引量:178H指数:11
供职机构:中山大学中山医学院寄生虫学教研室
研究主题:弓形虫 SAG1 DNA免疫 真核表达重组质粒 体外扩增
许小琴
作品数:93被引量:287H指数:9
供职机构:扬州大学兽医学院
研究主题:女贞子 富硒 热应激 硒 板蓝根多糖